Clinicopathologic significance of TROP2 and phospho-TROP2 in gastric cancer.
TROP2
clinicopathologic feature
gastric cancer
immunohistochemistry
pTROP2
Journal
Molecular and clinical oncology
ISSN: 2049-9450
Titre abrégé: Mol Clin Oncol
Pays: England
ID NLM: 101613422
Informations de publication
Date de publication:
May 2021
May 2021
Historique:
received:
28
08
2020
accepted:
19
01
2021
entrez:
5
4
2021
pubmed:
6
4
2021
medline:
6
4
2021
Statut:
ppublish
Résumé
Trophoblast cell-surface antigen 2 (TROP2) is a transmembrane glycoprotein expressed in epithelial cells. Increased TROP2 expression has been reported to be associated with malignant progression in most carcinomas; however, TROP2 has a tumor-suppressive function in certain types of cancer. Since the function of TROP2 is controversial, the present study subsequently aimed to clarify the clinicopathologic significance of TROP2 and pTROP2 expression in human gastric cancer (GC). The cases of 704 patients with GC who underwent gastrectomy were retrospectively analyzed. The expression levels of TROP2 and pTROP2 in each tumor were evaluated by immunohistochemistry. The association between the clinicopathologic features of patients with GC and the levels of TROP2 and pTROP2 in their tumors was analyzed. Increased TROP2 and pTROP2 expression was identified in 330 (46.9%) and 306 (43.5%) of the 704 patients with GC, respectively. Increased TROP2 expression was associated with the histological intestinal type, high tumor invasion depth (T3/T4), lymph node metastasis, lymphatic invasion and venous invasion. By contrast, increased pTROP2 expression was associated with intestinal type, low tumor invasion depth (T1/2), no lymph node metastasis and no lymphatic invasion. Increased TROP2 expression was associated with poorer overall survival (OS) (P<0.01; log rank test), whereas increased pTROP2 expression was significantly associated with improved OS (P<0.01; log rank test). In conclusion, increased expression levels of TROP2, but not pTROP2, may be associated with the metastatic ability of GC, resulting in poor prognosis of patients with GC.
Identifiants
pubmed: 33815794
doi: 10.3892/mco.2021.2267
pii: MCO-0-0-02267
pmc: PMC8010512
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105Informations de copyright
Copyright: © Kushiyama et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Lancet Oncol. 2018 May;19(5):583-584
pubmed: 29567072
Genes Cancer. 2015 Mar;6(3-4):84-105
pubmed: 26000093
Gynecol Oncol. 2019 Jan;152(1):185-193
pubmed: 30429055
Mod Pathol. 2008 Feb;21(2):186-91
pubmed: 18084248
Rom J Morphol Embryol. 2011;52(3 Suppl):1107-12
pubmed: 22119833
Genes Dev. 2012 Oct 15;26(20):2271-85
pubmed: 23070813
Virchows Arch. 2006 Jan;448(1):52-8
pubmed: 16220299
Int J Colorectal Dis. 2009 Aug;24(8):875-84
pubmed: 19421758
Cancer Res. 2008 Oct 1;68(19):8113-21
pubmed: 18829570
Br J Cancer. 2005 Jun 20;92(12):2097-101
pubmed: 15956962
Eur J Cancer. 2010 Mar;46(5):944-53
pubmed: 20060709
J Clin Pathol. 2009 Feb;62(2):152-8
pubmed: 18930986
Cancer Treat Rev. 2018 Sep;69:90-100
pubmed: 29957366
Biochim Biophys Acta. 2009 Dec;1796(2):309-14
pubmed: 19683559
EMBO Mol Med. 2012 Jun;4(6):472-85
pubmed: 22419550
Protein Expr Purif. 2013 Sep;91(1):69-76
pubmed: 23872121
Clin Cancer Res. 2005 Jun 15;11(12):4357-64
pubmed: 15958618
Nat Rev Cancer. 2008 Jan;8(1):11-23
pubmed: 18097461
Oncotarget. 2016 Feb 2;7(5):6136-45
pubmed: 26716416
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
J Biol Chem. 2019 Jul 26;294(30):11513-11524
pubmed: 31177095
JAMA Oncol. 2017 Apr 1;3(4):524-548
pubmed: 27918777
Oncotarget. 2014 Oct 15;5(19):9281-94
pubmed: 25238142
Br J Cancer. 2008 Oct 21;99(8):1290-5
pubmed: 18813308
Cell Signal. 2015 Jul;27(7):1325-35
pubmed: 25817572
Biochem Pharmacol. 2010 Oct 15;80(8):1115-24
pubmed: 20599789